ArticleBMJ open2025
Study protocol of a pilot randomised controlled trial assessing the feasibility and acceptability of RecoverEsupport: a digital health intervention to enhance recovery in women undergoing surgery for breast cancer.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- RecoverEsupport-A Digital Health Intervention for Recovery After Breast Cancer Surgery: Feasibility and Acceptability Outcomes from a Pilot Randomized Controlled Trial.JMIR formative research · 2026Trial
- Enhanced recovery after breast surgery: a review of international evidence and nursing challenges in China.American journal of translational research · 2026Review
- Acceptability of the RecoverEsupport Digital Health Intervention Among Patients Undergoing Breast Cancer Surgery: Qualitative Study.Journal of medical Internet research · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInternationally, breast cancer is the second most diagnosed cancer with approximately 2.3 million people diagnosed each year. 40% will require a mastectomy which has an average length of hospital stay of 1-2 days. Enhanced Recovery After Surgery (ERAS) guidelines include the following patient-managed recommendations: early mobilisation, early eating and drinking, opioid minimisation and physiotherapy exercises. Low adherence rates to these recommendations suggest that patients need support to do these things. A digital health intervention (DHI) may provide an effective, cost-effective and scalable solution. This pilot trial aims to assess the feasibility of conducting a trial of RecoverEsupport and the acceptability of the RecoverEsupport intervention to support patients to recover from breast cancer surgery. METHODS AND ANALYSIS: Participants will be recruited from the perioperative clinic and breast surgery units at a major cancer hospital in New South Wales, Australia and randomised (1:1) to receive (1) control: usual care or (2) intervention: usual care plus RecoverEsupport. The DHI incorporates the following evidence-based behaviour change strategies: education, self-monitoring and feedback and prompts and cues. The primary trial aims are to assess the feasibility of the trial and the acceptability of the RecoverEsupport intervention. The secondary aims are to assess preliminary efficacy and cost-effectiveness regarding the length of hospital stay. Data regarding patient behaviours related to patient-managed ERAS recommendations, Quality of Life, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Quality of Recovery (QOR-15), Anxiety (Hospital Anxiety and Depression Scale), hospital readmissions, emergency department presentations and health service utilisation postdischarge will also be collected. ETHICS AND DISSEMINATION: This study has been approved by the Human Research Ethics Committees of the Hunter New England Local Health District (2022/ETH02010), the University of Newcastle (H-2023-0298) and the Calvary Mater Newcastle (2022/STE03757). Trial outcomes will be disseminated via peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12624000417583.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.